The company posted a net profit of ₹81.3 crore for the quarter, down 45.7% from ₹149.6 crore in the corresponding period last year. Revenue, however, rose 10% year-on-year to ₹1,157.8 crore from ₹1,055.5 crore earlier.
Operating performance improved significantly during the quarter. EBITDA surged 61.6% to ₹151.7 crore from ₹94 crore a year ago, while EBITDA margin expanded to 13% from 8.9%, reflecting improved operational efficiencies and better cost management.
Following the earnings announcement, shares of Akums Drugs and Pharmaceuticals fell in trade. The stock touched an intraday low of ₹557 and was trading 3.4% lower at ₹522 on the NSE as of 1:27 PM.
The board recommended a final dividend of ₹1 per equity share and a special dividend of ₹2 per equity share for FY26, subject to shareholder approval at the upcoming annual general meeting.
The company has fixed July 3, 2026, as the record date for determining shareholder eligibility for the dividend payout.
Also Read: HAL Q4 Results: Operating performance weak but better than feared; Stock cools from highs
The latest earnings follow a relatively steady performance in the December quarter, when the company had reported modest profit growth alongside stronger revenue and operating performance.
In Q3 FY26, revenue had risen 14.8% year-on-year to ₹1,159.5 crore, while EBITDA increased 21.3% to ₹147 crore, with margins expanding to 12.7%.
